Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide [Al(OH)3] in Adults
Latest Information Update: 03 Oct 2021
At a glance
- Drugs HIL 214 (Primary)
- Indications Norovirus infections
- Focus Adverse reactions
- Sponsors LigoCyte Pharmaceuticals; Takeda
Most Recent Events
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2012 Preliminary results presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 02 Apr 2012 Planned end date changed from 1 Mar 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.